Evaluation of effectiveness of the PlasmaJet Surgical device in the treatment of Advanced Stage Ovarian Cancer. Will the use of the PlasmaJet device improve the rate of complete cytoreductive surgery for advanced stage ovarian cancer: a randomized controlled trial in The Netherlands (PlaComOv-study). - PlaComOv

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 330 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•- patients with epithelial ovarian, tuba or peritoneal carcinoma FIGO IIIB-IV
•who are fit enough to undergo radical cytoreductive surgery as discussed in the
•MDO. Patients can either be scheduled for primary cytoreduction or for interval
•cytoreduction after neoadjuvant chemotherapy.
•- patients should understand the patient information form and sign informed
•- pre-operative CT scan meets criteria for resectability

•- patients who are not willing to participate or not able to give their
•informed consent (language barrier) and patients who are not willing to undergo
•extensive surgery.
•- patients who are unfit to undergo extensive surgery (assessed by
•gynaecologist and anaesthesiologist and discussed in MDO).
•- patients who are not fit enough to get the standard complete chemotherapy
•(six cycles platinum based chemotherapy, e.g. carboplatin/paclitaxel))
•(assessed by medical oncologist and discussed in MDO).
•- patients with a non-epithelial, borderline ovarian tumour or an ovarian
•metastasis of another primary tumour.
•- patients with recurrence of ovarian cancer.

发起方